Treatment of patients with Covid-19 associated pneumonia using intravenous injection of allogenic pooled olfactory mucosa-derived mesenchymal stem cells
During the implementation of the project, it is planned to develop a method for the treatment
of severe covid-19 associated interstitial pneumonia using allogeneic mesenchymal stem cells.
The positive outlook for the effectiveness of MSCs is due to the following:
- knowledge of the leading role of immunopathogenetic mechanisms in the development of
acute interstitial lung diseases and the pronounced immunomodulating properties of MSCs;
- high tropism of MSCs to lung tissue when administered intravenously;
- the ability of MSCs to stimulate tissue regeneration and the effective use of MSCs in
the treatment of acute damage to the myocardium and kidneys, which will contribute to
the treatment of multiple organ failure;
- positive results of preclinical studies of the method of treatment of viral pneumonia in
animals, and the first clinical studies in patients.
Biological: Allogenic pooled olfactory mucosa-derived mesenchymal stem cells
Allogenic pooled olfactory mucosa-derived mesenchymal stem cells
Other: Standard treatment according to the Clinical protocols
Standard treatment according to the Clinical protocols
Inclusion Criteria:
- PCR-confirmed Covid-19 pneumonia
- respiratory failure
Exclusion Criteria:
- diagnosed cancer
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
Minsk, Belarus